A 41-year-old scientist with a genetic death sentence is rewriting the rules of ALS prevention, and he may have outsmarted the family curse that killed his mother and sisters before age 40.
Story Snapshot
- Jeff Vierstra carries the deadly FUS gene mutation that killed his mother at 38 and his two sisters—all from aggressive familial ALS—but remains symptom-free after three years of experimental gene-silencing treatment.
- He enrolled in the presymptomatic trial in 2020 after meeting Columbia University researchers at a conference, becoming the first known patient to receive the therapy before symptoms appeared.
- His muscle electrical activity normalized within one year of treatment with ulefnersen, an antisense oligonucleotide that silences the mutant FUS gene through spinal infusions every few months.
- Both sisters extended their lives modestly on the same treatment after symptoms began—Erin survived three years, Leigh four before an unrelated head injury—but Vierstra’s presymptomatic start appears to be the critical difference.
- Columbia’s Eleanor and Lou Gehrig ALS Center published results from the first 12 patients in May 2025, confirming the drug reduces toxic protein without side effects and offering hope for genetic screening-based prevention.
The Family Curse That Spans Generations
Genealogical records stretching back to the late 1800s reveal a haunting pattern in the Vierstra family tree: relatives dying in their 30s and 40s from an unidentified killer. Jeff Vierstra’s mother succumbed to ALS approximately nine months after her first symptoms appeared, when Jeff was only two years old. His aunts met similar fates in their prime years.
The culprit, researchers would later discover, was a mutation in the FUS gene—a rare hereditary form of amyotrophic lateral sclerosis that produces toxic protein aggregates, destroying motor neurons with merciless efficiency and compressing entire lives into brutal, abbreviated chapters.
A Chance Meeting Changes Everything
The trajectory of the Vierstra family story pivoted during a 2018 ALS conference in Barbados. Jeff Vierstra, by then a scientist himself, shared his family’s grim history with Columbia University researchers. His revelation prompted genetic testing that confirmed what the death records suggested: his sisters Erin and Leigh carried the FUS mutation.
By 2018, Dr. Neil Shneider’s team had already demonstrated in a Nature Medicine study that Ionis Pharmaceuticals’ ulefnersen could silence the mutant FUS gene in mice, delaying neurological damage. The FDA approved expanded access for human trials, and Erin and Leigh enrolled after developing symptoms. Jeff faced a choice: wait for the inevitable or gamble on prevention.
Betting on Science Before Symptoms Strike
Summer 2020 marked an unprecedented moment in ALS research. While his sisters battled advancing symptoms, Jeff Vierstra enrolled in the Columbia trial despite having no clinical manifestations of disease. His only red flag was abnormal electrical activity in his muscles detected by electromyography—an early warning system showing motor neuron stress.
The treatment regimen involves spinal infusions of ulefnersen, an antisense oligonucleotide that effectively tells cells to ignore the mutant FUS gene instructions. Within one year, Vierstra’s EMG readings normalized.
Dr. Shneider described the moment as transforming from “difficult” to a validation of their hypothesis: catching the disease before symptoms could prevent the cascade of destruction entirely.
The Brutal Math of Timing
The contrast between presymptomatic and symptomatic treatment outcomes tells a stark story. Erin and Leigh Vierstra both received the same drug, the same protocol, and care from the same research team. Erin survived approximately three years on treatment; Leigh made it to four years before dying from an unrelated head injury.
Both outcomes represented modest extensions compared to their mother’s nine-month decline, suggesting the therapy slowed but couldn’t reverse established damage.
Jeff Vierstra, meanwhile, has sailed past three years symptom-free, skiing, skydiving, hiking, and working—outliving the age at which his mother died and engaging in activities his sisters never experienced after diagnosis. The difference appears to hinge entirely on starting treatment before the motor neurons began their irreversible death spiral.
What This Means for ALS Prevention
FUS mutations account for only one to five percent of familial ALS cases, which themselves represent roughly ten percent of all ALS diagnoses. The numbers seem small, but the implications stretch far beyond this genetic subset.
Columbia’s May 2025 publication on the first 12 patients confirmed what Vierstra’s case suggested: ulefnersen reduces toxic FUS protein in the brain and spinal cord without significant side effects. Autopsy results from an early patient who died despite treatment showed measurable protein reduction, proving the drug reaches its target.
The data supports a paradigm shift from treating ALS after diagnosis to preventing it through genetic screening and early intervention. Dr. Shneider and his Columbia team have launched the Silence ALS initiative, aiming to extend personalized antisense oligonucleotide approaches to other rare ALS-causing mutations.
The Hope and the Uncertainty
Jeff Vierstra’s own words capture the psychological transformation of his experience: “Maybe this is working. I can start thinking about the future.” For someone whose entire adult life unfolded under the shadow of genetic certainty—watching family members die young, knowing his turn would come—the ability to plan beyond next year represents a revolution.
Dr. Shneider frames the achievement as making ALS “livable” rather than curable, a distinction grounded in scientific humility. Vierstra remains on treatment with infusions continuing every few months. Long-term data beyond three years doesn’t yet exist.
The trial’s scale remains modest at 12 patients. Questions persist about durability, optimal treatment windows, and whether similar strategies can work for the 90 percent of ALS cases without clear genetic targets.
Scientist whose mother and sisters died of ALS complications hopes experimental treatment will save his life https://t.co/9PQCDmuZYL
— CBS News (@CBSNews) April 5, 2026
Yet the conservative, common-sense view here aligns with measured optimism: when families face hereditary death sentences, proactive intervention grounded in rigorous science deserves pursuit.
Vierstra’s case demonstrates that individual initiative—attending that conference, volunteering for an unproven therapy—combined with pharmaceutical innovation and academic research can produce tangible results. His sisters’ participation, though they didn’t survive, generated the autopsy data proving the drug’s mechanism.
Their sacrifice wasn’t in vain. The Vierstra family’s multi-generational tragedy may ultimately yield a preventive framework that spares future families from repeating their history. For now, Jeff skis, works, and lives—each symptom-free day an answered prayer and a data point pushing medicine toward a future where genetic determinism loses its grip.
Sources:
Jeff’s Story: Defying a Family History of ALS Through a New Drug Trial – Columbia Doctors
The FUS Involved in ALS – UTMB MD News Podcast
